Navigation Links
Symposium to explore role nanoparticles may play in disease
Date:4/2/2008

BETHESDA, Md. (April 2, 2008) Two Mayo Clinic researchers who study the role nanoparticles may play in hardening of the arteries and in the formation of kidney stones, will lead a symposium on how these super-small particles may affect the bodys physiology. The symposium will take place April 8 at the Experimental Biology conference in San Diego.

Nanoparticles are a thousand times smaller than the bacteria, E. coli, but recent advances in microscopy have allowed researchers to watch them interact with cells in the body, said Virginia M. Miller and John C. Lieske of the Mayo Clinic College of Medicine. They will lead the symposium, Using nanotechnology to answer physiological questions.

One of the questions physiologists want to explore is whether nanoparticles can cause diseases such as atherosclerosis, kidney stones, gall stones and periodontal disease. Dr. Lieske is investigating how nano-sized crystals in the kidney can lead to the development of kidney stones. Dr. Miller has been studying the link between atherosclerosis (hardening of the arteries) and nanoparticles which calcify within the arteries.

A fuller audio interview with the researchers is available at www.lifelines.tv.

New technology: promise and peril?

Nanotechnology presents intriguing possibilities and some troubling unknowns. The technology is already applied in commercial products as disparate as flame resistant materials and cosmetics. In addition, the technology holds promise in the development of medications that can target precise areas of the body, such as a tumor.

Because of their size, nanoparticles may more easily gain entry to the body, where the longterm effects are unknown. Dr. Miller has found that some nanoparticles cause inflammation when injected into the blood vessels of animals, an early step in the development of atherosclerosis.

Using the latest in microscopy, Dr. Miller has begun to observe nanoparticles from atherosclerotic tissue. She hopes to determine how these particles gain access to cells and whether the interaction eventually leads to cell activation or death leading to calcification.

Kidneys stones start as tiny calcifications which later become larger and eventually develop into kidney stones. Dr. Lieske hypothesizes that the nanoparticle causes the initial calcification. Once that happens, other processes can take place that results in a kidney stone.

It is not yet known where nanoparticles that are implicated in kidney stones and atherosclerosis originate whether our bodies contain them naturally or we obtain them from the environment.

Miller said research should proceed to determine if nanoparticles are safe over the long term. We may not know some of the consequences until further down the road she said.

Dr. Miller and Dr. Lieske will moderate a program on nanotechnology at Experimental Biology. The speakers are Vitaly Vodyanoy of the University of Auburn; Robert Lee of The Ohio State University; Kevin D. Gillis of the University of Missouri-Columbia and Farooq Shiekh of the Mayo Clinic College of Medicine will present at the symposium.


'/>"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
Source:Eurekalert

Related medicine news :

1. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
2. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
3. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
4. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
5. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
6. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
7. AAAS symposium to address significant effects of the male parent in reproductive success
8. Symposium on drug-resistant diseases set for annual AAAS conference
9. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
10. Experts Offer Global Benefits Strategies at Symposium
11. AST to Address New Concept in Organ Allocation at March 13-16 Winter Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
Breaking Medicine Technology: